Abstract
The ubiquitin-proteasome pathway (UPP), which influences essential cellular functions including cell growth, differentiation, apoptosis, signal transduction, antigen processing and inflammatory responses, has been considered as one of the most important cellular protein degradation approaches. Proteasome functions as a gatekeeper, which controls the execution of protein degradation and plays a critical role in the ubiquitin-proteasome pathway. The unfolding of the close connection between proteasome and cancer provides a potential strategy for cancer treatment by using proteasome inhibitors. Small molecular inhibitors of varied structures and potency against proteasome have been discovered in recent years, with bortezomib and carfilzomib having been successfully approved for clinical application while some other promising candidates are currently under clinical trials. Herein, we review the development history of drugs and candidates that target the 20S proteasome, structure-activity relationships (SARs) of various proteasome inhibitors, and related completed or ongoing clinical trials.
Keywords: Cancer, clinical development, marketed, proteasome, proteasome inhibitor, SAR.
Current Medicinal Chemistry
Title:Clinical and Marketed Proteasome Inhibitors for Cancer Treatment
Volume: 20 Issue: 20
Author(s): Jiankang Zhang, Peng Wu and Yongzhou Hu
Affiliation:
Keywords: Cancer, clinical development, marketed, proteasome, proteasome inhibitor, SAR.
Abstract: The ubiquitin-proteasome pathway (UPP), which influences essential cellular functions including cell growth, differentiation, apoptosis, signal transduction, antigen processing and inflammatory responses, has been considered as one of the most important cellular protein degradation approaches. Proteasome functions as a gatekeeper, which controls the execution of protein degradation and plays a critical role in the ubiquitin-proteasome pathway. The unfolding of the close connection between proteasome and cancer provides a potential strategy for cancer treatment by using proteasome inhibitors. Small molecular inhibitors of varied structures and potency against proteasome have been discovered in recent years, with bortezomib and carfilzomib having been successfully approved for clinical application while some other promising candidates are currently under clinical trials. Herein, we review the development history of drugs and candidates that target the 20S proteasome, structure-activity relationships (SARs) of various proteasome inhibitors, and related completed or ongoing clinical trials.
Export Options
About this article
Cite this article as:
Zhang Jiankang, Wu Peng and Hu Yongzhou, Clinical and Marketed Proteasome Inhibitors for Cancer Treatment, Current Medicinal Chemistry 2013; 20 (20) . https://dx.doi.org/10.2174/09298673113209990122
DOI https://dx.doi.org/10.2174/09298673113209990122 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plastid Molecular Pharming I. Production of Oral Vaccines via Plastid Transformation
Mini-Reviews in Medicinal Chemistry Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy COVID-19 Related Publications Focusing on Cancer: Systematic Review of a Delicate Balance
Clinical Cancer Drugs Flu Viral Multiplex Testing and its Implication for COVID-19 Testing
New Emirates Medical Journal Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets Current Evaluation of the Millennium Phytomedicine- Ginseng (II): Collected Chemical Entities, Modern Pharmacology, and Clinical Applications Emanated from Traditional Chinese Medicine
Current Medicinal Chemistry A2B Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Histone Deacetylase Inhibitors: The Abbott Experience
Current Medicinal Chemistry From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Current Pharmaceutical Design Patent Selections:
Recent Patents on Anti-Infective Drug Discovery ANN-QSAR Model for Virtual Screening of Androstenedione C-Skeleton Containing Phytomolecules and Analogues for Cytotoxic Activity Against Human Breast Cancer Cell Line MCF-7
Combinatorial Chemistry & High Throughput Screening The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance
Current Medicinal Chemistry D-allose: Molecular Pathways and Therapeutic Capacity in Cancer
Current Molecular Pharmacology New Cyclohexylamine-dithiocarbamate Derivatives as Potential Anti-microbial Agents
Letters in Drug Design & Discovery Role of Natural Plant Products Against Hemagglutinin-esterase (HE) of Human Coronavirus
Current Nutraceuticals Medicinal Chemistry Approaches for Glucokinase Activation to Treat Type 2 Diabetes
Current Medicinal Chemistry Why is Glycine not a Part of the Osmoticum in the Urea-rich Cells?
Protein & Peptide Letters The Chemistry of Nascent Oxacalix[n]hetarene (n≥4): A Review
Current Organic Chemistry